文献速递生殖医学

配子捐赠者扩展性携带者筛查的应用

The use of expanded carrier screening of gamete donors.
PubMed 文献 · Hum Reprod · 2021-01-01

本研究通过在线检索综述现有扩展性携带者筛查(ECS)panel,并分析Cryos International捐赠者的基因检测结果。结果显示,在46/47基因的ECS panel下,17.6%(155/883)的候选捐赠者因筛查结果被拒绝。被拒绝者中α-地中海贫血携带者占比最高(19.4%),其次为脊髓性肌萎缩(15.5%)和囊性纤维化(14.8%)。

要点

  • 使用46/47基因ECS panel,17.6%的候选捐赠者被拒绝。
  • 被拒绝者中α-地中海贫血携带者占19.4%,脊髓性肌萎缩占15.5%,囊性纤维化占14.8%。
  • 研究提示需欧盟统一法规允许配子捐赠者与受者基因匹配,以避免拒绝已知携带者。

核心结论

  • 使用扩展性携带者筛查(ECS)panel(男性46个基因,女性47个基因)导致17.6%的候选捐赠者被拒绝。
  • 被拒绝的捐赠者中,α-地中海贫血携带者比例最高(19.4%),其次为脊髓性肌萎缩(15.5%)和囊性纤维化(14.8%)。
  • 研究强调需要一致的欧盟法规和指南,允许配子捐赠者与受者进行基因匹配,从而避免拒绝已知携带者。

研究设计与样本

  • 通过在线搜索综述当前可供捐赠者使用的孕前ECS panel。
  • 分析Cryos International捐赠者的基因检测结果,以确定基于ECS被拒绝的捐赠者数量。
  • 数据由Cryos International提供,该机构使用其定制的ECS panel筛查捐赠者。

主要发现

  • 共审查了16家公司和42个相关ECS panel,这些panel共覆盖2673种独特疾病,平均筛查329种疾病,但没有一种疾病被所有panel共同覆盖。
  • Cryos International对男性筛查46种疾病,对女性筛查47种疾病。
  • 在883名候选捐赠者中,17.6%(155/883)基于ECS结果被拒绝。
  • 被拒绝者中,α-地中海贫血携带者占19.4%(30/155),脊髓性肌萎缩携带者占15.5%(24/155),囊性纤维化携带者占14.8%(23/155)。

临床怎么用

  • 在辅助生殖技术中,对配子捐赠者进行ECS可识别携带者,但可能导致捐赠者数量下降。
  • 临床可考虑对捐赠者与受者进行基因匹配,而非直接拒绝已知携带者,以维持捐赠者供应。

局限性

  • Panel信息来源于公司网站,可能不准确。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

STUDY QUESTION: What are the sperm and egg donor rejection rates after expanded carrier screening (ECS)? SUMMARY ANSWER: Using an ECS panel looking at 46/47 genes, 17.6% of donors were rejected. WHAT IS KNOWN ALREADY: The use of ECS is becoming commonplace in assisted reproductive technology, including testing of egg and sperm donors. Most national guidelines recommend rejection of donors if they are carriers of a genetic disease. If the use of ECS increases, there will be a decline in the number of donors available. STUDY DESIGN, SIZE, DURATION: A review of the current preconception ECS panels available to donors was carried out through an online search. The genetic testing results of donors from Cryos International were analysed to determine how many were rejected on the basis of the ECS. PARTICIPANTS/MATERIALS, SETTING, METHODS: Data on gamete donors and their carrier status was provided by Cryos International, who screen donors using their own bespoke ECS panel. The ECS panels identified through the review were compared to the Cryos International panel and data. MAIN RESULTS AND THE ROLE OF CHANCE: A total of 16 companies and 42 associated ECS panels were reviewed. There were a total of 2673 unique disorders covered by the panels examined, with a mean of 329 disorders screened. None of these disorders were common to all panels. Cryos International screen 46 disorders in males and 47 in females. From 883 candidate donors, 17.6% (155/883) were rejected based on their ECS result. Carriers of alpha-thalassaemia represented the largest proportion of those rejected (19.4%, 30/155), then spinal muscular atrophy (15.5%, 24/155) and cystic fibrosis (14.8%, 23/155). LIMITATIONS, REASONS FOR CAUTION: Panel information was found on company websites and may not have been accurate. WIDER IMPLICATIONS OF THE FINDINGS: This study highlights the need for consistent EU regulations and guidelines that allow genetic matching of gamete donors to their recipients, preventing the need to reject donors who are known carriers. A larger ECS panel would be most beneficial; however, this would not be viable without matching of donors and recipients. STUDY FUNDING/COMPETING INTEREST(S): No specific funding was obtained. J.C.H. is the founder of Global Women Connected, a platform to discuss women's health issues and the Embryology and PGD Academy, who deliver education in clinical embryology. She has been paid to give a lecture by Cryos in 2019. A-B.S. is an employee of Cryos International. TRIAL REGISTRATION NUMBER: N/A.

来源:Hum Reprod,查看原文。版权归原作者所有。

引用

  1. Payne MR, Skytte AB, Harper JC, et al. The use of expanded carrier screening of gamete donors. Hum Reprod. 2021. PMID: 33842976. doi:10.1093/humrep/deab067

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。